News
Latest news related to non-animal research
-
9 October 2025OECD : Guidance on omics, NAMs for DART, Biotech Act, 2026 MPS World Summit Call for abstract, Deciphering brain organoids and more
NEWS, REPORTS & POSITION STATEMENTS 1. OECD : Guidance on good practices and standardisation of omics data Omics technologies are increasingly being used in regulatory toxicology as part of New Approach Methodologies (NAMs). These applications include identifying molecular points of departure for […]
Read more -
2 October 2025OOC regulatory perspective, Incorporating NAMs into medicines development, NIH Organoids SOM Center and Replication Prize, and more
NEWS, REPORTS & POSITION STATEMENTS 1. European Commission scientific strategies for sovereignty Strategy on Research and Technology Infrastructures On 15 September 2025, the EC adopted a new, long-term European Strategy on Research and Technology Infrastructures. Research infrastructures and technology infrastructures […]
Read more -
23 September 2025AI-Powered On-Chip Systems, NIH landmark whole-person project, ASPIS Winners, Embolization-on-a-chip
NEWS, REPORTS & POSITION STATEMENTS 1. Top 5 Must-Read Articles on AI-Powered On-Chip Systems AI is colliding with organoids, organs-on-chips, and digital-twin models, and reshapes how we discover, test, and de-risk new therapies. The OOC company Canchip has curated essential […]
Read more -
18 September 2025French O&OOC industry collective appeal, ToxTracker® Approved by OECD, Psychedelics meet human brain organoids
NEWS, REPORTS & POSITION STATEMENTS 1. Urgent relaunch of the AFNOR S96R commission : F3OCI collective appeal The French organoid and organ-on-a-chip industry (F3OCI), alongside academic, industrial and biobank infrastructure players, published an open letter calling for the AFNOR S96R commission […]
Read more -
10 September 2025Putting human biology at the center, AI lab-pilot transition, First self-contained OoC workstation, Organoids as immune-organ interaction models
NEWS, REPORTS & POSITION STATEMENTS 1. The drug development shift : Putting human biology at the center The biopharma industry continues to face unacceptable high attrition rates in clinical development. Most failures trace back to : 1. Lack of efficacy – animal […]
Read more
